Key Takeaways
Veracyte Inc. (NASDAQ: VCYT) will present data from two pivotal Phase III trials for its cancer diagnostic tests at the American Society of Clinical Oncology's 2026 annual meeting, held May 29 to June 2 in Chicago.
"The OPTIMA trial results represent a major milestone in precision breast oncology and will provide Level 1A evidence supporting Prosigna-guided treatment decisions," Kelly Marcom, Veracyte’s medical director for Breast Cancer, said in a statement.
The OPTIMA study, which enrolled over 4,400 patients, was designed to determine if the Prosigna test can identify which patients with high-risk early-stage breast cancer can safely avoid chemotherapy. Separately, data from the ENZAMET trial will be presented showing the Decipher Prostate test's ability to predict which patients with metastatic prostate cancer are most likely to benefit from the addition of docetaxel chemotherapy to standard hormone therapy.
"Together, these studies provide practice-changing evidence supporting the use of Veracyte’s tests in guiding treatment decisions across cancer types," said Phillip Febbo, the company's chief scientific and medical officer. The findings may allow clinicians to better match treatment intensity to individual patient risk, avoiding unnecessary side effects.
The first results from the OPTIMA trial will be presented on Saturday, May 30, during a breast cancer session. The study, led by University College London, is a randomized, non-inferiority trial that could transform how a large population of breast cancer patients are treated.
Later that day, during a genitourinary cancer session, data from the ENZAMET trial will be presented. This analysis is expected to provide Level 1B evidence on using the Decipher Prostate Genomic Classifier to guide treatment intensification for patients with metastatic, hormone-sensitive prostate cancer.
The data from these large, randomized trials provides the highest level of clinical evidence, which could lead to inclusion in treatment guidelines and broader insurance reimbursement. The market will watch for the full data presentations on May 30 to assess the clinical and commercial impact for Veracyte.
This article is for informational purposes only and does not constitute investment advice.
